20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Praxis Precision Medicines Inc (PRAX) operates in the BIOTECHNOLOGY industry and is headquartered in Boston, United States with about 168 employees. Its market capitalization is roughly $8 billion. In the fiscal year ended 2025-12-31, PRAX reported $0M in revenue and ($303M) in net income.
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
Interactive charts & full statements →
| Income statement | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $9M | $2M | $1M | $0M | $0M | $0M | $0M |
| Gross Profit | ($206M) | $0M | ($144M) | ($84M) | ($1M) | ($2M) | ($1M) | ($1M) | $0M |
| Gross Margin % | — | — | -1682.0% | -3445.8% | -80.0% | — | — | — | — |
| Operating Income (EBIT) | ($357M) | ($326M) | ($200M) | ($126M) | ($215M) | ($167M) | ($62M) | ($36M) | ($23M) |
| Operating Margin % | — | — | -2340.3% | -5164.4% | -14684.8% | — | — | — | — |
| Net Income | ($327M) | ($303M) | ($183M) | ($123M) | ($213M) | ($167M) | ($62M) | ($36M) | ($27M) |
| Net Margin % | — | — | -2137.5% | -5037.9% | -14554.1% | — | — | — | — |
| EBITDA | ($326M) | ($303M) | ($182M) | ($123M) | ($215M) | ($167M) | ($62M) | ($35M) | ($26M) |
| Earnings Per Share (EPS) | $-13.83 | $-13.48 | $-10.21 | $-18.69 | $-69.33 | $-58.96 | $-24.23 | $-31.01 | $-29.99 |
| Shares Outstanding (M) | 29M | 23M | 18M | 7M | 3M | 3M | 3M | 1M | 1M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $0M | $0M | $0M | $7M | $0M | $0M |
| Gross Profit | — | $0M | ($78M) | ($66M) | ($63M) | ($61M) | ($49M) | ($42M) | ($27M) |
| Gross Margin % | — | — | — | — | — | — | -654.2% | -13767.9% | -7535.9% |
| Operating Income (EBIT) | ($97M) | ($106M) | ($97M) | ($78M) | ($76M) | ($75M) | ($64M) | ($57M) | ($37M) |
| Operating Margin % | — | — | — | — | — | — | -857.0% | -18819.5% | -10500.8% |
| Net Income | ($84M) | ($93M) | ($89M) | ($74M) | ($71M) | ($69M) | ($59M) | ($52M) | ($33M) |
| Net Margin % | — | — | — | — | — | — | -786.3% | -17188.7% | -9153.2% |
| EBITDA | — | ($93M) | ($89M) | ($74M) | ($71M) | ($69M) | ($59M) | ($52M) | ($33M) |
| Earnings Per Share (EPS) | $-2.87 | $-3.20 | $-3.95 | $-3.36 | $-3.31 | $-3.29 | $-2.94 | $-2.75 | $-1.74 |
| Shares Outstanding (M) | — | 29M | 23M | 22M | 21M | 21M | 20M | 19M | 19M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($283M) | ($249M) | ($132M) | ($111M) | ($185M) | ($125M) | ($53M) | ($33M) | ($21M) |
| Capital Expenditures (CapEx) | $0M | $0M | $0M | $0M | $0M | $1M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($283M) | ($249M) | ($132M) | ($111M) | ($185M) | ($126M) | ($53M) | ($33M) | ($21M) |
| FCF Margin % | — | — | -1540.5% | -4543.8% | -12669.9% | — | — | — | — |
| Dividends Paid | — | — | — | — | $1M | — | $1M | — | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($78M) | ($86M) | ($77M) | ($65M) | ($55M) | ($53M) | ($56M) | ($28M) | ($27M) |
| Capital Expenditures (CapEx) | ($1M) | $0M | $0M | $0M | $0M | $0M | $0M | $0M | $0M |
| Free Cash Flow (FCF) | ($79M) | ($86M) | ($77M) | ($65M) | ($55M) | ($53M) | ($56M) | ($28M) | ($27M) |
| FCF Margin % | — | — | — | — | — | — | -752.0% | -9106.0% | -7640.9% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $1.4B | $938M | $483M | $88M | $115M | $293M | $303M | $48M | $20M |
| Cash & Cash Equivalents | $475M | $357M | $215M | $81M | $62M | $139M | $297M | $45M | $18M |
| Total Liabilities | $49M | $60M | $38M | $18M | $39M | $42M | $16M | $8M | $5M |
| Total Debt (Short + Long-Term) | — | $0M | $1M | $1M | $1M | $4M | $1M | $1M | $0M |
| Total Shareholders' Equity | $1.3B | $878M | $445M | $70M | $76M | $251M | $287M | $40M | $15M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive PRAX viewer.
This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी
About TickerBase · Data methodology & sources · Privacy · Terms